Tags

Type your tag names separated by a space and hit enter

Renin-angiotensin-aldosterone system inhibitors in heart failure.
Clin Pharmacol Ther 2013; 94(4):459-67CP

Abstract

Heart failure (HF) is a very common condition that, despite advances in treatment, carries significant morbidity and mortality. Although there is good evidence for the treatment of HF with reduced ejection fraction (HFrEF), the treatment for HF with preserved ejection fraction (HFpEF) is not well defined. The renin-angiotensin-aldosterone system (RAAS) has been shown to be an effective target in the treatment of HFrEF using angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone blockade, although the evidence in HFpEF is less clear. This review aims to look first at the evidence for these drugs, and second at the newer drugs that act on the RAAS, namely, direct renin inhibitors, neutral endopeptidase inhibitors, vasopeptidase inhibitors, and angiotensin receptor blockers.

Authors+Show Affiliations

Division of Cardiovascular & Diabetes Medicine, Medical Research Institute, University of Dundee, Dundee, UK.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

23852393

Citation

Shearer, F, et al. "Renin-angiotensin-aldosterone System Inhibitors in Heart Failure." Clinical Pharmacology and Therapeutics, vol. 94, no. 4, 2013, pp. 459-67.
Shearer F, Lang CC, Struthers AD. Renin-angiotensin-aldosterone system inhibitors in heart failure. Clin Pharmacol Ther. 2013;94(4):459-67.
Shearer, F., Lang, C. C., & Struthers, A. D. (2013). Renin-angiotensin-aldosterone system inhibitors in heart failure. Clinical Pharmacology and Therapeutics, 94(4), pp. 459-67. doi:10.1038/clpt.2013.135.
Shearer F, Lang CC, Struthers AD. Renin-angiotensin-aldosterone System Inhibitors in Heart Failure. Clin Pharmacol Ther. 2013;94(4):459-67. PubMed PMID: 23852393.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Renin-angiotensin-aldosterone system inhibitors in heart failure. AU - Shearer,F, AU - Lang,C C, AU - Struthers,A D, Y1 - 2013/07/12/ PY - 2013/06/13/received PY - 2013/07/08/accepted PY - 2013/7/16/entrez PY - 2013/7/16/pubmed PY - 2013/12/16/medline SP - 459 EP - 67 JF - Clinical pharmacology and therapeutics JO - Clin. Pharmacol. Ther. VL - 94 IS - 4 N2 - Heart failure (HF) is a very common condition that, despite advances in treatment, carries significant morbidity and mortality. Although there is good evidence for the treatment of HF with reduced ejection fraction (HFrEF), the treatment for HF with preserved ejection fraction (HFpEF) is not well defined. The renin-angiotensin-aldosterone system (RAAS) has been shown to be an effective target in the treatment of HFrEF using angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and aldosterone blockade, although the evidence in HFpEF is less clear. This review aims to look first at the evidence for these drugs, and second at the newer drugs that act on the RAAS, namely, direct renin inhibitors, neutral endopeptidase inhibitors, vasopeptidase inhibitors, and angiotensin receptor blockers. SN - 1532-6535 UR - https://www.unboundmedicine.com/medline/citation/23852393/Renin_angiotensin_aldosterone_system_inhibitors_in_heart_failure_ L2 - https://doi.org/10.1038/clpt.2013.135 DB - PRIME DP - Unbound Medicine ER -